Articles tagged with Osteoporosis
The European Menopause and Andropause Society recommends a daily calcium intake of 700-1200mg for postmenopausal women to reduce the risk of osteoporosis. Calcium-rich foods should be prioritized over supplements, as excessive intake may cause harm.
Long-term treatment of osteoporosis is crucial for postmenopausal women to reduce fracture risk. New guidelines recommend reevaluating fracture risk after 3-5 years of bisphosphonate treatment and considering alternative therapies or continued treatment.
Researchers are developing a 'lab-on-a-chip' platform to study cellular communication in bone remodeling, aiming to improve our understanding of bone health and disease. The platform could also be used to test medications meant to halt bone loss, offering a potential solution for osteoporosis and related conditions.
A new treatment for osteoporosis has shown significant improvements in bone density and fracture protection. The study found that romosozumab reduced the risk of vertebral fractures by 48% and clinical fractures by 27%, offering better protection against fractures for high-risk patients.
A study found that less than half of detectable vertebral fractures are reported by radiologists, particularly in non-musculoskeletal radiologists. This under-reporting can lead to delayed diagnosis and treatment of osteoporosis, increasing the risk of future hip fractures.
A new Australian study reveals hip fractures are a major public health issue with high morbidity and mortality rates. The research found that individuals with hip fractures were 3.5 times more likely to die within 12 months compared to non-injured counterparts, with excess mortality risk higher in males than females.
A massive genetic study has identified 153 new gene variants linked to osteoporosis, which could lead to the development of a new treatment. The study found that removing a strongly implicated gene GPC6 in animal models resulted in increased bone thickness.
Researchers at the University of British Columbia have developed a new osteoporosis treatment using a compound derived from red sage, selectively blocking Cathepsin K enzyme activity in bone tissue. This approach may prevent negative side effects associated with current treatments.
Researchers discovered a causal link between senescent cells and age-related bone loss in mice. Targeting these cells increased bone mass and strength. The study's findings suggest that senolytic drugs may have widespread application in treating multiple chronic diseases, including osteoporosis.
A study by Cornell University researchers found that prolonged bisphosphonate use can alter the composition of bone, making it more brittle and susceptible to fractures. The study suggests that long-term treatment beyond FDA recommendations may increase the risk of atypical femoral fractures.
Teriparatide therapy increases osteoblast activity and lifespan, but stopping treatment leads to increased fat cell formation in mice. This suggests therapies targeting parathyroid hormone receptors may prioritize osteoblast development over other cell fates.
A UTA professor has received a grant to design a biomedical device that stimulates bone growth and could be used to treat osteoporosis. The device aims to strengthen bones of people with low bone mass conditions.
A study of over 2,500 women found that even brief bursts of high-intensity exercise, equivalent to a 1-2 minute run, can improve bone health. The research suggests that short periods of weight-bearing activity are more beneficial than longer continuous periods.
A nationwide Swedish study linked alendronate treatment to a lower risk of hip fractures in elderly patients using medium to high doses of anti-inflammatory medication. The research also found that longer treatment duration was associated with a greater reduction in fracture risk.
A comprehensive review highlights the most effective treatment options for co-managing type 2 diabetes and osteoporosis. Researchers suggest using medications like Metformin and DPP-4 inhibitors to protect bone health. Meanwhile, insulin therapy is recommended for achieving glycemic control in patients with T2D and fractures.
A new class of drug, romosozumab, has been shown to rapidly and significantly reduce the risk of vertebral fractures in postmenopausal women with osteoporosis. In a clinical trial, women treated with romosozumab had a 83% lower risk of vertebral fracture compared to those receiving placebo.
The ACR's updated clinical guideline provides recommendations for assessing fracture risk and treatment for adults and special patient populations. For all age groups, the panel strongly recommends optimizing calcium and vitamin D intake and implementing lifestyle modifications to prevent glucocorticoid-induced osteoporosis.
Research at the University of Missouri School of Medicine highlights the importance of understanding risk factors and following treatment plans to prevent osteoporosis-related fractures. The study emphasizes the need for preventive screening methods, cost-effective medications, and patient education to effectively manage the disease.
Increased yogurt intake was associated with higher hip bone density and reduced osteoporosis risk in older women and men. Vitamin D supplements also showed a significant association with reduced risks in both sexes.
The American College of Physicians recommends treating women with osteoporosis with bisphosphonates or denosumab, while men may also benefit from treatment to reduce vertebral fracture risk. The guideline emphasizes the importance of medication adherence and avoids estrogen therapy due to its associated risks.
The American College of Physicians strongly recommends the use of generic bisphosphonates or denosumab to reduce fracture risk in women with osteoporosis. The guideline advises physicians to prescribe generics over brand-name drugs and discuss medication adherence with patients.
A study published in the New England Journal of Medicine reveals a genetic mutation that makes bone vulnerable to bisphosphonates, increasing the risk of atypical femur fractures. The discovery highlights the need for personalized treatment approaches to prevent this complication.
A French study found that direct communication with fracture patients through a dedicated case manager increased post-fracture BMD testing rates by 20%. This approach empowered patients to demand testing and care, closing the care gap in osteoporosis treatment.
A new study confirms denosumab's short-term and long-term safety in treating postmenopausal osteoporosis. Women on long-term treatment experienced no increase in adverse effects compared to those on placebo or shorter treatment durations.
A new study found denosumab safe for treating postmenopausal osteoporosis over an extended period. The monoclonal antibody showed no increased risk of adverse events after 6 years of treatment, confirming its excellent safety and tolerability profile.
A new study reveals that men are at a higher risk of mortality after osteoporosis-related fractures compared to women. The study found that men who require surgical treatment for an initial fracture are more likely to suffer a subsequent fracture within three years.
A recent study found that less than half of elderly hip fracture patients take vitamin D supplements, contradicting national recommendations. This suggests a need for improved advocacy and education about vitamin D supplementation.
A systematic review of 37 randomized controlled trials found that exercise had a positive impact on muscle mass and function in healthy older adults, while dietary supplementation showed less consistent benefits. The combined effect of exercise and nutrition intervention varied depending on the individual's baseline health status.
A new study by Imperial College London suggests that bisphosphonates, a commonly used treatment for osteoporosis, may increase the risk of 'micro-cracks' in bone, leading to reduced mechanical strength. The research found that patients taking the drugs had more microcracks and weaker bones than those who were not on the medication.
A large study of postmenopausal women who suffered a hip fracture found low rates of osteoporosis assessment and treatment. Regular doctor visits were the strongest predictor of osteoporosis diagnosis and treatment.
A new review identifies four main themes addressing gaps in osteoporosis care, including public awareness, reimbursement, and epidemiology. The authors stress the need for increased implementation of systematic approaches to prevent secondary fractures and improved management of patients with medicines negatively affecting bone health.
The IOF-ECTS Position Paper proposes measuring specific bone turnover markers to detect low adherence to oral bisphosphonates, a common issue in chronic diseases. This early identification enables discussion and intervention with patients, potentially improving treatment efficacy.
A new study of 119 children with osteogenesis imperfecta found that bisphosphonate treatment did not change the radiological appearance of femur fractures.
The current approaches to preventing hip fractures have shown limited efficacy, with only a 50% reduction in risk. A new review suggests exploring complementary approaches and surgical interventions for patients at high risk, including prophylactic nailing and bone grafting.
The American Association of Clinical Endocrinologists and American College of Endocrinology have released new osteoporosis guidelines recommending that all postmenopausal women aged 50 and older be evaluated for osteoporosis risk. Successful treatment is defined as stable or increasing bone mineral density with no evidence of new fract...
New York University College of Dentistry has received a grant to investigate potential new compounds for treating osteoporosis. The researchers aim to understand the molecular mechanisms of parathyroid hormone-a related protein and its analogs to develop better-tolerated treatments.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism reveals that menopausal hormone therapy (MHT) improves both bone mass and structure, with benefits persisting for at least two years after treatment ends.
The expert panel concludes that calcium and vitamin D supplements are generally appropriate for those with high risk of insufficiency and in individuals receiving osteoporosis treatment. The evidence favors use of calcium and vitamin D supplements for fracture reduction, particularly in those at greatest risk of insufficiency.
Early and aggressive treatment with biologic drugs may halt progressive bone loss in patients with RA. Biologic therapies targeting specific cytokines and signaling pathways show protective effects on the skeleton.
The implementation of Fracture Liaison Services (FLS) is crucial to identify and treat high-risk patients with osteoporosis, reducing the risk of secondary fractures. Studies have shown that FLS can significantly increase treatment rates and prevent secondary osteoporotic fractures.
The International Osteoporosis Foundation presented five researchers with prestigious Young Investigator Research Awards for their notable osteoporosis research. The award winners were selected from 168 abstracts and received a prize of $1000, a certificate, and the opportunity to present their work at a high-profile session.
A recent analysis of the ACTIVE trial results shows that abaloparatide-SC provides consistent protection against bone fractures in postmenopausal women with osteoporosis, regardless of baseline bone density or age. The therapy has been found to reduce fractures and increase bone mineral density in postmenopausal women with osteoporosis.
Abaloparatide stimulates bone formation without affecting resorption, reducing fractures in postmenopausal women with osteoporosis. The study's preclinical data are promising for continued development of abaloparatide as an osteoporosis treatment.
Researchers used genetic profiling to predict osteoporosis risk in individuals with high accuracy, improving classification by 12% compared to traditional clinical risk factors. The findings have the potential to revolutionize bone disease management and treatment for Australia's 1.2 million osteoporosis sufferers.
A new report by the International Osteoporosis Foundation identifies 10 major care gaps that are preventing early assessment and treatment of osteoporosis. The report highlights the need for better case finding, communication, and public awareness to tackle the global healthcare crisis arising from fragility fractures.
Researchers used ECIS to track stem cell transformation into bone tissue cells, revealing age-related differences in conversion rates and calcium secretion. The study provides new insights into the potential of adipose-derived stem cells for osteoporosis treatment.
Scientists at University of Würzburg have crystallized an antibody effective against Sclerostin, a protein involved in bone metabolism. The findings offer a promising treatment option for osteoporosis, a condition that affects elderly women and increases the risk of fractures.
The systematic review concludes that fixed or age-dependent thresholds are more effective in identifying individuals at high risk of fracture than the use of bone mineral density (BMD) values alone. However, intervention thresholds must be country-specific, according to the report.
A new study published in JAMA found that daily injection of the drug abaloparatide significantly reduced the risk of new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. The treatment also showed a more pronounced anabolic effect on bone compared to other osteoporosis drugs.
Research by University of North Texas historian Constance Hilliard reveals that West African women living in regions without dairy farming have a lower rate of postmenopausal hip fractures caused by osteoporosis than their East African peers. This paradox is due to genetic adaptation to low-calcium diets, which disadvantage bone strength.
A new review published by the IFCC-IOF Working Group for Standardisation of Bone Marker Assays supports the potential for bone turnover markers to provide clinically useful information. The study highlights the importance of standardization and harmonization of units for reporting serum/plasma CTX and PINP concentrations.
Researchers at the University of Nottingham have secured £1.2m to develop injectable stem cell-carrying materials to treat osteoporosis and other bone-thinning diseases. The targeted therapy aims to promote bone regeneration through a quick, easy, and minimally-invasive treatment.
Elderly patients with wrist fractures are more likely to have poor balance, increasing the risk of future injuries. Researchers recommend evaluating and treating balance deficiencies after a fracture to prevent further complications.
High-risk osteoporosis patients often underdiagnosed and undertreated, despite effective fracture-preventing medications. The authors call for improved diagnosis and therapy to prevent fractures in this high-risk population.
A recent study found that approximately one-third of women taking oral bisphosphonates continue to be at elevated risk for bone fracture. Despite the medication being effective in reducing fracture risk, various factors such as other medical conditions and fall-related problems contribute to this increased risk.
A survey by Northwell Health found that nearly 7 in 10 older adults with hip fractures are not informed about osteoporosis, despite the disease being a common cause of hip fractures. The study suggests that improved education and treatment for osteoporosis could reduce re-fracture rates and improve patient outcomes.
A new analysis suggests that the moderate effect of calcium and vitamin D on fracture prevention is not large enough to outweigh the potential increased risk of cardiovascular disease. For 65-year-old women at low risk of bone fracture, the risks may outweigh the benefits.
A consensus report from the International Osteoporosis Foundation Fracture Working Group recommends that patients with recent fractures should start osteoporosis medications as soon as possible. The panel agreed that anabolic agents like teriparatide may have a beneficial effect on fracture healing, while bisphosphonates may delay it.
Professor Serge Ferrari has been recognized with the International Osteoporosis Foundation's 2016 Olof Johnell Science Award for his significant work in bone health, genetics of osteoporosis, and bone remodeling. He is a leading thought leader in the field, known for translating new research findings into improved patient care.
Dr. Elias Hanna Saba, Chief Executive Director of the Palestinian Osteoporosis Prevention Society, was awarded the International Osteoporosis Foundation's Committee of National Societies Medal for his over 26 years of experience in bone and muscle health and patient education. The medal recognizes his dedication to expanding IOF's mess...